產品資訊 - Inactivated Influenza Vaccine For Human->aspalthic products

登入

加入會員

求助

Changchun Changsheng Life Sciences Ltd.

	Recommended Results

Inactivated Influenza Vaccine For Human

產品分類 :

化學->化學用品->aspalthic products

產品規格

Model No:	0.5 or 0.25ml/syringe

Country	CN
Minimum Order	5000
Payment Term	L/C,T/T

產品描述

Influenza Vaccine (Split Virion), Inactivated


 [Advantages] 
(1)Apply centrifugal purification and column chromatography purification technology to purifying virus and obtained the patent certificate of making use of Sepharose4FF column chromatography technology for vaccine manufacture. The product quality index is excellent and the purity is high;  
(2)Obtained National Ten Famous-brand Products Honor Certificate in pharmaceutical industry; 
(3)High-level GMT of conversion rate of serum antibody with safety and reliable effect for prevention; 
(4)Various Specifications: 
1)Vial type for adult: 0.5ml/vial for people above 3 years old; 
Vial type for children:0.25ml/vial for children from 6 to 35 months old; 
2)Syringe type for adult: 0.5ml/syringe for people above 3 years old; 
Syringe type for children:0.25ml/syringe for children from 6 to 35 months old; 
(5)Exclusively apply two dosage forms of pre-filled syringe from American BD Company and vial pack for security and convenience; 
(6)Rated as National New and Key Product by the Ministry of Science and Technology, Ministry of Foreign Trade and Economic Cooperation, State General Administration of Supervision, Inspection and Quarantine, State Environmental Protection Administration of China; rated as Excellent Technology Product by China Association for Science and Technology; award the Honor of Science and Technology Progress by Changchun City Administration of Science and Technology; 
(7)Successfully registered in over 20 countries and export to dozens of countries for consecutive years.


[Eligibles]


Susceptible individuals and persons liable to be afflicted with the associated complications, such as children, elderly persons and individuals in the epidemic area.


[Function and use]


The product can induce immunity against influenza virus in recipients following immunization. It is used to prevent the infections of the prevalent strains of influenza viruses.


[Description]


The influenza vaccine (split virion) is a preparation made from the WHO recommended prevalent strains of influenza virus type A and type B which are grown separately in embryonated chicken eggs. After incubation, the virus suspensions in allantoic cavities are harvested. The vaccine is prepared by inactivation, concentration, purification and disruption of the virus. It is a slightly milky-white liquid, containing thimerosal as a preservative.


Active constituent: Influenza haemagglutinin derived from each of prevalent influenza virus strains in that very year. (The name of each of virus strains and the content of haemagglutinin shall be included. )


Subsidiary materials: All the components of subsidiary materials approved shall be listed.


[Specifications]


0. 25 ml or 0.5 ml per container.  0.25 ml per single human dose (used for children aged between 6 months and 3 years) .shall contain 7.5 μg of influenza haemagglutinin of each influenza virus strain. 0.5 ml per single human dose (used for adult and children aged above 3 years) shall contain 15 μg of influenza haemagglutinin of each influenza virus strain.


[Administration and dosage] 
(1) Inject i. m. in the deltoid muscle of the lateral upper arm. 
(2) Inoculate before and during the epidemic season of influenza. Inject single human dose of 0.5 ml vaccine for adults and children aged above 3 years. Inject two human doses of 0.25 ml vaccine for children aged between 6 months and 3 years at intervals of 2-4 weeks. 
[Adverse reactions] 
Common adverse reactions 
(1) Pain, tenderness, redness, swelling and itching may occur at the injection sites generally within 24 hours after vaccination, which can be relieved spontaneously within 2-3 days in most cases.                 
(2) Transient fever may occur a and can be relieved spontaneously within a short period and need no particular treatment in most cases. 
Rare adverse reactions 
(1)Transient common cold symptoms and discomfort may occur after vaccination which can be relieved spontaneously and need no particular treatment.                 
(2) Severe fever: Physical therapy and symptomatic treatment shall be adopted to prevent febrile convulsion. 
Extremely rare adverse reactions 
(1) Allergic rash: Urticaria may occur generally within 72 hours after vaccination, if it occurs the recipients shall go to the clinic promptly and receive anti-anaphylactic treatment. 
(2) Anaphylactic shock: Anaphylactic shock may occur within one hour after vaccination, emergency measures shall be adopted immediately including prompt injection of adrenaline. 
(3) Allergic purpura: The recipients with allergic purpura shall go to t.he clinic promptly and receive anti-anaphylactic treatment with corticosteroid. If the treatment is inappropriate or delayed,  purpuric  nephritis may be complicated. 

<img src="http://i.bosscdn.com/product/1d/85/e4/25b2580c5f2d983e504dc14c7e.jpg@watermark=2&color=I0ZGRkZGRg%3D%3D&type=ZHJvaWRzYW5zZmFsbGJhY2s%3D&size=22&p=9&t=80&text=Y3MtdmFjY2luZS5ib3NzZ29vLmNvbQ%3D%3D" title="Infuenza Vaccine-PFS" alt="Infuenza Vaccine-PFS" /> 


 


 



 
ccls-vaccine.com

其他類似產品